The Oncology Institute, Inc. (TOI)

NASDAQ: TOI · IEX Real-Time Price · USD

0.524

+0.004 (0.77%)

At close: Jul 19, 2024, 4:00 PM

0.560

+0.036 (6.87%)

Pre-market: Jul 20, 2024, 9:28 AM EDT

The Oncology Institute Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	342.71	324.24	252.48	203	187.52	155.41
Revenue Growth (YoY)	25.30%	28.42%	24.37%	8.26%	20.66%	-
Cost of Revenue	285.27	264.67	200.39	162.16	150.64	125.46
Gross Profit	57.44	59.57	52.09	40.85	36.88	29.94
Selling, General & Admin	113.47	113.85	119.69	83.37	41.9	29.64
Other Operating Expenses	6.09	22.74	14.36	3.34	3.18	2.94
Operating Expenses	119.57	136.59	134.04	86.71	45.08	32.59
Operating Income	-62.12	-77.02	-81.95	-45.86	-8.2	-2.64
Interest Expense / Income	6.11	6.78	4.08	0.32	0.35	0
Other Expense / Income	-10.39	-15.88	-85.86	-34.88	6.27	-0.01
Pretax Income	-57.85	-67.91	-0.18	-11.3	-14.82	-2.64
Income Tax	-0.08	-0.04	-0.24	-0.67	-0.49	1.38
Net Income	-57.77	-67.88	0.07	-10.63	-14.32	-4.02
Shares Outstanding (Basic)	74	74	73	66	59	10
Shares Outstanding (Diluted)	74	74	81	66	59	10
Shares Change	1.07%	-8.51%	21.70%	12.03%	491.18%	-
EPS (Basic)	-0.81	-0.92	-	-0.16	-0.24	-402.14
EPS (Diluted)	-0.81	-0.92	-0.21	-0.16	-0.24	-402.14
Free Cash Flow	-40.08	-40.88	-67.29	-35.53	-0.69	2.41
Free Cash Flow Per Share	-0.54	-0.55	-0.92	-0.54	-0.01	0.24
Gross Margin	16.76%	18.37%	20.63%	20.12%	19.67%	19.27%
Operating Margin	-18.13%	-23.75%	-32.46%	-22.59%	-4.37%	-1.70%
Profit Margin	-16.86%	-20.93%	0.03%	-5.24%	-7.64%	-2.59%
Free Cash Flow Margin	-11.70%	-12.61%	-26.65%	-17.50%	-0.37%	1.55%
EBITDA	-45.64	-55.26	8.32	-7.64	-11.29	0.31
EBITDA Margin	-13.32%	-17.04%	3.29%	-3.76%	-6.02%	0.20%
Depreciation & Amortization	6.09	5.87	4.41	3.34	3.18	2.94
EBIT	-51.74	-61.14	3.91	-10.98	-14.47	-2.63
EBIT Margin	-15.10%	-18.86%	1.55%	-5.41%	-7.72%	-1.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).